Immuneering reports interim Phase 2a data: 39% ORR, 81% DCR in first-line pancreatic cancer

Immuneering Corp

As of May 26, 2025 cutoff: 1 CR, 13 PR (4 pending confirmation), 15 SD among 36 evaluable patients; DCR 81%, ORR 39%.
In 320 mg ITT population (n=34): 94% OS and 72% PFS at 6 months median follow-up; median OS and PFS not reached.
Grade≥3 TEAEs in ≥10% of 320 mg patients: anemia (18%) and neutropenia (15%); no Grade 5 events.
Additional data expected Q4 2025; pivotal trial of atebimetinib+mGnP in 1L pancreatic cancer planned for 2026, pending regulatory feedback Q4 2025.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.